Biomea Fusion is trading at $1.34, down 10.07%, after investors reacted to the BMF-650 Phase I topline readout being delayed from the third quarter to October 2026.
- The company terminated its proposed public offering, citing unfavorable market conditions; no securities were sold.
- Major U.S. indexes are modestly higher, indicating company-specific pressure.